Liquid Biopsy Assays:
Beyond Recurrence Detection in Post-Diagnosis Cancer Management
About this webinar
MRD is rapidly emerging as a key biomarker in therapy development and patient care, however, key challenges remain. Personalis is committed to addressing some of the most pressing needs in the liquid biopsy space.
In this webinar attendees will learn about the role of next-generation liquid biopsy assays in enabling:
- Earlier detection of disease recurrence
- Utility in more disease indications, and at earlier stages of disease
- Patient enrichment, screening/enrollment and surrogate endpoint analysis for clinical trials
- Higher resolution variant tracking
- Combining plasma and tissue analyses
Register to learn how liquid biopsy assays go beyond recurrence detection in post-diagnosis cancer management.
Who should attend
- Immuno-Oncology Clinical Development Programs
- Clinical Program Managers or Project Managers
- Biomarker and CDx Laboratory Directors and Scientists
- Chief Medical and Scientific Officers
- Bioinformatics and Genomics
- Medical Affairs
- Procurement
What you will learn
- Earlier detection of disease recurrence
- Utility in more disease indications, and at earlier stages of disease
- Patient enrichment, screening/enrollment and surrogate endpoint analysis for clinical trials
- Higher resolution variant tracking
- Combining plasma and tissue analyses
Featured Speakers
Dan Norton
Dan Norton is currently Associate Director of Product Management with a focus on liquid biopsies at Personalis, following a role as Senior Product Manager focused on immuno-oncology. Prior to this, Dan had several product management and business development roles at Bio-Rad Laboratories, Illumina, Althea Technologies and Bayer Healthcare. Dan has an MBA from University California, San Diego and a BS from University California, Los Angeles.
Partner for this event
Personalis
Personalis, Inc. is leading the oncology field in developing patient-centered diagnostics by delivering tumor-informed comprehensive insights. The Personalis NeXT Platform® and suite of products are designed to capture the complex and evolving understanding of cancer, providing biopharmaceutical partners and clinicians with information on 20,000 human genes and the immune system from a single tissue sample.
With NeXT PersonalTM these insights are expanded into a tumor-informed, ultra-sensitive ctDNA analysis, enabling earlier detection of disease recurrence (MRD) in a broader range of indications at earlier stages. Personalis operates a CAP/CLIA-accredited laboratory in the United States, delivering our NeXT DxTM test, a comprehensive genomic testing solution that enables physicians to identify potential targeted and/or immunotherapy options, evidence of drug resistance and clinical trial options for patients with solid tumors. Personalis also operates a Wholly Foreign-Owned Enterprise and laboratory in China, with HGRAC approval of NeXT Platform to provide retrospective testing in clinical trials.
Related webinars
More from Personalis.
NGS Solutions for FFPE Materials — Maximizing Immuno-Oncology Insights with Challenging Clinical Samples
NeXT Liquid Biopsy: A High-Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics – Broadcast 2
NeXT Liquid Biopsy: A High-Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics – Broadcast 1
Neoantigens for Personalized Cancer Vaccines: Comprehensive Identification and Effective Selection
Overcoming the Challenges of Immuno-Oncology Biomarker Discovery: From Sample to Analytics
Shifting the Cancer Vaccine Paradigm: NGS Best Practices for Developing Personalized Neoantigen Vaccines